News

Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had granted Orphan Drug Designation to BPS-804 for osteogenesis imperfecta, a rare, chronic genetic

aGvHD is a leading cause of death following an allogeneic stem cell transplant due to the transplanted immune cells attacking the patient’s tissues. It results in a very

This divestiture is being done by way of slump sale (as a going concern) and includes all related fixed assets (land and building), current assets, current liabilities, and

As part of the deal, Adynxx stockholders will become the majority owners of Alliqua’s outstanding common stock on a fully-diluted basis. The public clinical-stage pharmaceutical firm will involve

CT900 is a targeted therapy that combines targeting folate receptor α (FRα) and inhibiting thymidylate synthase. The small molecule compound selectively enters cancer cells that over express folate

MEI Pharma chief medical officer Robert Mass said: “We are excited to be working with BeiGene to explore the potential of ME-401 in combination with zanubrutinib. “Combinatorial approaches

While Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, COM701 is an investigational anti-PVRIG antibody. Apart from the clinical trial collaboration, Bristol-Myers Squibb has agreed to make

The regulator’s Oncologic Drugs Advisory Committee voted unanimously recommending approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan, to treat adult patients in three proposed indications.

The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma. MaxCyte CEO Doug Doerfler said: “The initiation of